Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Autonomix Medical, Inc. (AMIX)

4.6735 -0.1565 (-3.24%)
As of 10:42:42 AM EDT. Market Open.
Chart Range Bar
Loading chart for AMIX
  • Previous Close 4.8300
  • Open 4.6000
  • Bid 4.7400 x 100
  • Ask 6.0900 x 200
  • Day's Range 4.5510 - 4.7300
  • 52 Week Range 2.4400 - 32.5500
  • Volume 66,034
  • Avg. Volume 4,496,097
  • Market Cap (intraday) 4.538M
  • Beta (5Y Monthly) -1.16
  • PE Ratio (TTM) --
  • EPS (TTM) -31.0500
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 58.80

Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders of nervous system. The company's technology platform includes a catheter-based system incorporating microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.

autonomix.com

--

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 9/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

AMIX
59.54%
S&P 500 (^GSPC)
11.79%

1-Year Return

AMIX
80.13%
S&P 500 (^GSPC)
18.46%

3-Year Return

AMIX
99.85%
S&P 500 (^GSPC)
69.47%

5-Year Return

AMIX
99.85%
S&P 500 (^GSPC)
69.16%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY26
Revenue --
Earnings -2.67M
Profit Margin 0.00%

Q2

FY26

Q3

FY26

Q4

FY26

-6M
-4M
-2M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

42.00
58.80 Average
4.6735 Current
75.60 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 2/17/2026
Analyst Maxim Group
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 5 -> 2

Statistics

View More

Valuation Measures

Annual
As of 8/27/2026
  • Market Cap

    5.49M

  • Enterprise Value

    -5.20M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    1.74

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -157.81%

  • Return on Equity (ttm)

    -315.99%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -16.11M

  • Diluted EPS (ttm)

    -31.0500

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    3.46M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -7.62M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

4.6735 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: